CN103274970B - 抗病毒化合物和方法 - Google Patents
抗病毒化合物和方法 Download PDFInfo
- Publication number
- CN103274970B CN103274970B CN201310097430.5A CN201310097430A CN103274970B CN 103274970 B CN103274970 B CN 103274970B CN 201310097430 A CN201310097430 A CN 201310097430A CN 103274970 B CN103274970 B CN 103274970B
- Authority
- CN
- China
- Prior art keywords
- virus
- compound
- compounds
- mmol
- guanidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC=Cc1cccc2c1CC*CC2 Chemical compound CC=Cc1cccc2c1CC*CC2 0.000 description 3
- QENGPZGAWFQWCZ-UHFFFAOYSA-N Cc1c[s]cc1 Chemical compound Cc1c[s]cc1 QENGPZGAWFQWCZ-UHFFFAOYSA-N 0.000 description 2
- DUAZFYUNWBILMU-UHFFFAOYSA-N Cc1c(C)[n](C)nc1C Chemical compound Cc1c(C)[n](C)nc1C DUAZFYUNWBILMU-UHFFFAOYSA-N 0.000 description 1
- KJRRQXYWFQKJIP-UHFFFAOYSA-N Cc1c[o]cc1 Chemical compound Cc1c[o]cc1 KJRRQXYWFQKJIP-UHFFFAOYSA-N 0.000 description 1
- XQQBUAPQHNYYRS-UHFFFAOYSA-N Cc1ccc[s]1 Chemical compound Cc1ccc[s]1 XQQBUAPQHNYYRS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005903360 | 2005-06-24 | ||
| AU2005903360A AU2005903360A0 (en) | 2005-06-24 | Anti-viral compounds and methods |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800226410A Division CN101208297B (zh) | 2005-06-24 | 2006-06-23 | 抗病毒化合物和方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103274970A CN103274970A (zh) | 2013-09-04 |
| CN103274970B true CN103274970B (zh) | 2015-02-25 |
Family
ID=37570036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310097430.5A Expired - Fee Related CN103274970B (zh) | 2005-06-24 | 2006-06-23 | 抗病毒化合物和方法 |
| CN2006800226410A Active CN101208297B (zh) | 2005-06-24 | 2006-06-23 | 抗病毒化合物和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800226410A Active CN101208297B (zh) | 2005-06-24 | 2006-06-23 | 抗病毒化合物和方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8669280B2 (enExample) |
| EP (2) | EP2826770B1 (enExample) |
| JP (2) | JP5373392B2 (enExample) |
| KR (2) | KR20140072101A (enExample) |
| CN (2) | CN103274970B (enExample) |
| AU (1) | AU2006261593B2 (enExample) |
| BR (2) | BRPI0612309B8 (enExample) |
| CA (1) | CA2612403C (enExample) |
| DK (2) | DK1902017T3 (enExample) |
| ES (2) | ES2710662T3 (enExample) |
| NZ (3) | NZ564398A (enExample) |
| PL (2) | PL1902017T3 (enExample) |
| PT (2) | PT1902017E (enExample) |
| SG (1) | SG163517A1 (enExample) |
| WO (1) | WO2006135978A1 (enExample) |
| ZA (1) | ZA200800256B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ544671A (en) * | 2003-06-26 | 2009-02-28 | Biotron Ltd | Antiviral compounds and methods |
| EP2826770B1 (en) * | 2005-06-24 | 2018-09-12 | Biotron Limited | Acylguanidine compounds with antiviral activity |
| JP2010528051A (ja) | 2007-05-23 | 2010-08-19 | シガ・テクノロジーズ・インコーポレーテッド | デング感染症の治療または予防のための抗ウイルス薬 |
| CN101827589B (zh) * | 2007-08-03 | 2016-08-17 | 拜伊特朗有限公司 | 抗丙型肝炎病毒的组合物及方法 |
| AU2013219202B2 (en) * | 2007-08-03 | 2016-12-08 | Biotron Limited | Hepatitis C antiviral compositions and methods |
| WO2009022633A1 (ja) * | 2007-08-10 | 2009-02-19 | Astellas Pharma Inc. | 二環式アシルグアニジン誘導体 |
| US20120041036A1 (en) * | 2009-02-09 | 2012-02-16 | Isao Kinoyama | Substituted acylguanidine derivatives (as amended) |
| EP2394987A4 (en) * | 2009-02-09 | 2012-09-05 | Astellas Pharma Inc | ACYLGUANIDINDERIVAT |
| TW201116281A (en) | 2009-08-06 | 2011-05-16 | Astellas Pharma Inc | N atom containing ring acylguanidine derivatives |
| US20120027752A1 (en) | 2010-07-22 | 2012-02-02 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| US9126106B1 (en) | 2010-11-05 | 2015-09-08 | Wms Gaming, Inc. | Promotional content coordination in wagering game machines |
| EP2651885A1 (en) * | 2010-12-16 | 2013-10-23 | Abbvie Inc. | Anti-viral compounds |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| HRP20220355T1 (hr) | 2015-09-16 | 2022-05-13 | Gilead Sciences, Inc. | Postupci za liječenje infekcija coronaviridae |
| EP3579833B1 (en) * | 2017-02-08 | 2022-01-05 | Biotron Limited | Methods of treating influenza |
| TW201836615A (zh) | 2017-03-14 | 2018-10-16 | 美商基利科學股份有限公司 | 治療貓冠狀病毒感染之方法 |
| CA3059777C (en) | 2017-05-01 | 2023-02-21 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| MX2022006274A (es) * | 2019-11-26 | 2022-10-13 | Biotron Ltd | Metodos de tratamiento de la infeccion por vih-1. |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
| AU2021281351A1 (en) | 2020-05-29 | 2023-01-19 | Gilead Sciences, Inc. | Remdesivir treatment methods |
| PH12022553530A1 (en) | 2020-06-24 | 2024-06-24 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| PL4200301T3 (pl) | 2020-08-24 | 2025-06-09 | Gilead Sciences, Inc. | Związki fosfolipidowe i ich zastosowania |
| ES2985995T3 (es) | 2020-08-27 | 2024-11-08 | Gilead Sciences Inc | Compuestos y métodos para el tratamiento de infecciones víricas |
| TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| EP4346772A1 (en) | 2021-05-26 | 2024-04-10 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| CA3228162A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| EP4436576A4 (en) * | 2021-11-24 | 2025-09-17 | Biotron Ltd | METHODS FOR TREATING SARS-CoV-2 INFECTION |
| CA3243944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | COMPOUNDS AND METHODS OF TREATMENT FOR VIRAL INFECTIONS |
| US20230295172A1 (en) | 2022-03-02 | 2023-09-21 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| WO2023167055A1 (ja) * | 2022-03-03 | 2023-09-07 | 日本曹達株式会社 | 抗ウイルス剤 |
| CR20240367A (es) | 2022-03-03 | 2024-09-30 | Gilead Sciences Inc | Compuestos antivirales y métodos de elaboración y uso de los mismos. |
| CR20240365A (es) | 2022-03-03 | 2024-10-04 | Gilead Sciences Inc | Compuestos antivirales y métodos de elaboración y uso de los mismos |
| AU2023283718A1 (en) | 2022-06-06 | 2024-12-12 | Gilead Sciences, Inc. | Methods for treatment of viral infections including sars-cov-2 |
| EP4547334A1 (en) | 2022-06-29 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| CN115260100B (zh) * | 2022-08-08 | 2023-12-12 | 赛诺瑞生物医药技术(无锡)有限公司 | 一种用于制备冠状病毒治疗药物的取代酰基胍类化合物和用途 |
| EP4665737A1 (en) | 2023-02-16 | 2025-12-24 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| US20250090537A1 (en) | 2023-08-31 | 2025-03-20 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250084088A1 (en) | 2023-08-31 | 2025-03-13 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250099476A1 (en) | 2023-09-06 | 2025-03-27 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20250109157A1 (en) | 2023-09-28 | 2025-04-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1138029A (zh) * | 1995-05-22 | 1996-12-18 | 赫彻斯特股份公司 | 氟苯基取代的链烯基羧酸-胍，其制备方法，作为药物或诊断剂的应用以及含有此化合物的药物 |
| EP0810206A1 (de) * | 1996-05-29 | 1997-12-03 | Hoechst Aktiengesellschaft | Substituierte 2-Naphtohoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2734904A (en) * | 1956-02-14 | Xcxnhxc-nh | ||
| US4251545A (en) | 1979-09-19 | 1981-02-17 | Gaf Corporation | Fungicidal process using 1-(alkoxyaroyl)guanidines |
| US4544670A (en) * | 1982-08-24 | 1985-10-01 | William H. Rorer, Inc. | Method of treating coccidiosis with acyl guanidines |
| JPH0218632A (ja) | 1988-07-07 | 1990-01-22 | Matsushita Electric Ind Co Ltd | 論理ゲート評価装置と論理ゲート評価方法 |
| DE3929582A1 (de) * | 1989-09-06 | 1991-03-07 | Hoechst Ag | Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| DE4328869A1 (de) | 1993-08-27 | 1995-03-02 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE4421536A1 (de) * | 1994-06-20 | 1995-12-21 | Hoechst Ag | Perfluoralkylgruppen tragende phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| JPH08225513A (ja) * | 1994-12-21 | 1996-09-03 | Kanebo Ltd | ナフトイルグアニジン誘導体 |
| DE19527305A1 (de) | 1995-07-26 | 1997-01-30 | Hoechst Ag | Substituierte Zimtsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19606355A1 (de) * | 1996-02-12 | 1997-08-14 | Schering Ag | Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung |
| AUPO545297A0 (en) * | 1997-03-04 | 1997-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
| US20030113352A1 (en) * | 2001-12-14 | 2003-06-19 | The Regents Of The University Of California | Neutralization of stratum corneum to treat hyperkeratotic skin lesions |
| CA2551169A1 (en) * | 2002-12-23 | 2004-07-08 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery |
| CN1794988B (zh) * | 2003-03-31 | 2010-07-28 | 株式会社·R-技术上野 | 用于治疗血管渗透性过高疾病的组合物 |
| NZ544671A (en) * | 2003-06-26 | 2009-02-28 | Biotron Ltd | Antiviral compounds and methods |
| US20070099968A1 (en) | 2004-06-26 | 2007-05-03 | Biotron Limited | Antiviral compounds and methods |
| EP2826770B1 (en) * | 2005-06-24 | 2018-09-12 | Biotron Limited | Acylguanidine compounds with antiviral activity |
| ES2320042T3 (es) * | 2005-10-19 | 2009-05-18 | F. Hoffmann-La Roche Ag | Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida. |
| JP5727842B2 (ja) | 2011-04-12 | 2015-06-03 | 日野自動車株式会社 | 車両のインストルメントパネル構造 |
| KR101331921B1 (ko) * | 2013-01-16 | 2013-11-21 | 에스케이플래닛 주식회사 | 영유아의 안전을 위한 스마트 인터랙션 서비스를 제공하는 장치 및 방법, 이를 이용한 시스템 |
-
2006
- 2006-06-23 EP EP13197255.6A patent/EP2826770B1/en active Active
- 2006-06-23 CA CA2612403A patent/CA2612403C/en active Active
- 2006-06-23 ES ES13197255T patent/ES2710662T3/es active Active
- 2006-06-23 EP EP06741271.8A patent/EP1902017B1/en active Active
- 2006-06-23 ES ES06741271.8T patent/ES2491217T3/es active Active
- 2006-06-23 DK DK06741271.8T patent/DK1902017T3/da active
- 2006-06-23 CN CN201310097430.5A patent/CN103274970B/zh not_active Expired - Fee Related
- 2006-06-23 JP JP2008517277A patent/JP5373392B2/ja active Active
- 2006-06-23 NZ NZ564398A patent/NZ564398A/en unknown
- 2006-06-23 DK DK13197255.6T patent/DK2826770T3/en active
- 2006-06-23 PL PL06741271T patent/PL1902017T3/pl unknown
- 2006-06-23 AU AU2006261593A patent/AU2006261593B2/en active Active
- 2006-06-23 CN CN2006800226410A patent/CN101208297B/zh active Active
- 2006-06-23 PT PT67412718T patent/PT1902017E/pt unknown
- 2006-06-23 BR BRPI0612309A patent/BRPI0612309B8/pt active IP Right Grant
- 2006-06-23 NZ NZ610715A patent/NZ610715A/en not_active IP Right Cessation
- 2006-06-23 NZ NZ596107A patent/NZ596107A/xx not_active IP Right Cessation
- 2006-06-23 BR BR122020006906A patent/BR122020006906B8/pt active IP Right Grant
- 2006-06-23 PL PL13197255T patent/PL2826770T3/pl unknown
- 2006-06-23 KR KR1020147010199A patent/KR20140072101A/ko not_active Ceased
- 2006-06-23 ZA ZA200800256A patent/ZA200800256B/xx unknown
- 2006-06-23 WO PCT/AU2006/000880 patent/WO2006135978A1/en not_active Ceased
- 2006-06-23 US US11/922,281 patent/US8669280B2/en active Active
- 2006-06-23 KR KR1020087001886A patent/KR101419327B1/ko active Active
- 2006-06-23 PT PT13197255T patent/PT2826770T/pt unknown
- 2006-06-23 SG SG201004454-3A patent/SG163517A1/en unknown
-
2012
- 2012-09-24 JP JP2012209126A patent/JP5616410B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-05 US US14/071,870 patent/US9440926B2/en active Active
-
2016
- 2016-09-12 US US15/262,075 patent/US10683263B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1138029A (zh) * | 1995-05-22 | 1996-12-18 | 赫彻斯特股份公司 | 氟苯基取代的链烯基羧酸-胍，其制备方法，作为药物或诊断剂的应用以及含有此化合物的药物 |
| EP0810206A1 (de) * | 1996-05-29 | 1997-12-03 | Hoechst Aktiengesellschaft | Substituierte 2-Naphtohoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103274970B (zh) | 抗病毒化合物和方法 | |
| CN101827589B (zh) | 抗丙型肝炎病毒的组合物及方法 | |
| JP3490739B2 (ja) | ３，４，５−置換ベンゾイルグアニジン、それらの製法ならびにそれらを含有する医薬 | |
| AU2013205388B2 (en) | Antiviral compounds and methods | |
| HK1206330B (en) | Acylguanidine compounds with antiviral activity | |
| HK1109615B (en) | Antiviral acylguanidine compounds | |
| JPS60204757A (ja) | β−オキソ−α−カルバモイル−ピロリルプロピオニトリル類 | |
| AU2013219202B2 (en) | Hepatitis C antiviral compositions and methods | |
| JPH09227496A (ja) | オルト置換されたベンゾイルグアニジン、それらの製造方法、医薬または診断薬としてのそれらの使用およびそれらを含有する医薬 | |
| HK1141718B (en) | Hepatitis c antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-c-methyladenosine or 2'-c-methylcytidine | |
| MXPA96005675A (en) | Diguanididas of bencenodicarboxilicos substitute acids, procedure for its preparation, its employment as a diagnostic medicine or agent, as well as a medication that the |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150225 |